Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 172.6% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 694,361 shares of the company's stock after purchasing an additional 439,599 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.99% of Health Catalyst worth $3,145,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Nepsis Inc. increased its holdings in Health Catalyst by 2,072.1% in the 1st quarter. Nepsis Inc. now owns 2,090,812 shares of the company's stock worth $9,471,000 after acquiring an additional 1,994,555 shares in the last quarter. First Light Asset Management LLC increased its holdings in Health Catalyst by 22.0% in the 4th quarter. First Light Asset Management LLC now owns 5,241,121 shares of the company's stock worth $37,055,000 after acquiring an additional 944,631 shares in the last quarter. Alyeska Investment Group L.P. increased its holdings in Health Catalyst by 74.4% in the 4th quarter. Alyeska Investment Group L.P. now owns 2,019,380 shares of the company's stock worth $14,277,000 after acquiring an additional 861,150 shares in the last quarter. Penn Capital Management Company LLC purchased a new stake in Health Catalyst in the 4th quarter worth approximately $3,506,000. Finally, Palogic Value Management L.P. purchased a new stake in Health Catalyst in the 4th quarter worth approximately $2,262,000. Hedge funds and other institutional investors own 85.00% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on the stock. Citigroup lowered shares of Health Catalyst from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $6.50 to $3.50 in a report on Friday, August 8th. Canaccord Genuity Group reduced their target price on shares of Health Catalyst from $10.00 to $9.00 and set a "buy" rating for the company in a report on Thursday, May 8th. Wells Fargo & Company reduced their target price on shares of Health Catalyst from $10.00 to $6.00 and set an "overweight" rating for the company in a report on Monday, August 11th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $4.00 price objective (down from $9.00) on shares of Health Catalyst in a report on Friday, August 8th. Finally, Evercore ISI cut their price objective on shares of Health Catalyst from $5.00 to $4.00 and set an "in-line" rating for the company in a report on Wednesday, July 9th. Seven equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, Health Catalyst has an average rating of "Hold" and an average target price of $6.18.
Read Our Latest Report on HCAT
Health Catalyst Trading Down 0.3%
Shares of NASDAQ:HCAT traded down $0.01 on Friday, hitting $2.92. 911,699 shares of the company's stock were exchanged, compared to its average volume of 837,189. Health Catalyst, Inc. has a 12 month low of $2.52 and a 12 month high of $9.24. The stock has a market capitalization of $205.48 million, a price-to-earnings ratio of -1.93 and a beta of 1.46. The business's 50 day simple moving average is $3.74 and its two-hundred day simple moving average is $4.16. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.83 and a quick ratio of 1.24.
Health Catalyst Profile
(
Free Report)
Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.
Featured Stories
Before you consider Health Catalyst, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Health Catalyst wasn't on the list.
While Health Catalyst currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access